Benzingaยท2025-09-25 05:48Core Viewpoint - PepGen Inc. experienced a significant surge in share price, rising 119.55% to $5.84 in after-hours trading following the announcement of an underwritten public offering of common stock and pre-funded warrants [1][2]. Group 1: Public Offering Details - The biotech company based in Cambridge, Massachusetts, has initiated an underwritten public offering, with Leerink Partners and Stifel SF serving as joint book-running managers. The underwriters have a 30-day option to purchase additional shares [2]. - The offering is conducted under a Form S-3 registration statement that was declared effective by the SEC on July 8, 2024 [3]. Group 2: Use of Proceeds - PepGen plans to utilize the net proceeds from the offering to fund ongoing research and clinical development, specifically for the FREEDOM-DM1 and FREEDOM2-DM1 trials targeting neuromuscular diseases. Additional funds will be allocated for working capital and general corporate purposes [4]. Group 3: Market Performance Context - Despite the recent surge, PepGen's stock has faced challenges over the past year, with a decline of 69.11%. The company currently holds a market capitalization of $87.25 million and has an average daily trading volume of 572,850 shares. The stock has fluctuated between a 52-week low of $0.89 and a high of $9.94 [5]. - In regular trading, PEPG closed at $2.66, reflecting a daily increase of 36.41% [5].